CY1122182T1 - Ανοσοκατασταλτικες φαρμακοτεχνικες μορφες - Google Patents
Ανοσοκατασταλτικες φαρμακοτεχνικες μορφεςInfo
- Publication number
- CY1122182T1 CY1122182T1 CY20191101097T CY191101097T CY1122182T1 CY 1122182 T1 CY1122182 T1 CY 1122182T1 CY 20191101097 T CY20191101097 T CY 20191101097T CY 191101097 T CY191101097 T CY 191101097T CY 1122182 T1 CY1122182 T1 CY 1122182T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical forms
- api
- pharmaceutically acceptable
- immunosuppressant
- immunosuppressant pharmaceutical
- Prior art date
Links
- 229960003444 immunosuppressant agent Drugs 0.000 title 1
- 230000001861 immunosuppressant effect Effects 0.000 title 1
- 239000003018 immunosuppressive agent Substances 0.000 title 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007790 solid phase Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε μια φαρμακευτική σύνθεση στερεάς φάσης, η οποία αποτελείται από ένα ή περισσότερα φαρμακευτικώς αποδεκτά έκδοχα και ένα δραστικό φαρμακευτικό συστατικό ("API"), το οποίο είναι μια ένωση του τύπου Α1 ή Α2 ή ένα φαρμακευτικώς αποδεκτό άλας, επιδιαλύτωμα ή υδρίτης αυτής, όπου το API δεν εκτίθεται σε μια βασική ένωση.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11150431 | 2011-01-07 | ||
| PCT/EP2012/050151 WO2012093161A1 (en) | 2011-01-07 | 2012-01-05 | Immunosuppressant formulations |
| EP12700262.4A EP2661261B1 (en) | 2011-01-07 | 2012-01-05 | Immunosuppressant formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122182T1 true CY1122182T1 (el) | 2020-11-25 |
Family
ID=44022942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101097T CY1122182T1 (el) | 2011-01-07 | 2019-10-22 | Ανοσοκατασταλτικες φαρμακοτεχνικες μορφες |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US20130273161A1 (el) |
| EP (2) | EP3590507A1 (el) |
| JP (2) | JP6111202B2 (el) |
| KR (2) | KR101951966B1 (el) |
| CN (1) | CN103458877B (el) |
| AR (2) | AR084801A1 (el) |
| AU (1) | AU2012204835B2 (el) |
| BR (1) | BR112013017302B1 (el) |
| CA (1) | CA2823616C (el) |
| CL (1) | CL2013001979A1 (el) |
| CO (1) | CO6761402A2 (el) |
| CY (1) | CY1122182T1 (el) |
| DK (1) | DK2661261T3 (el) |
| EA (1) | EA026144B9 (el) |
| EC (1) | ECSP13012812A (el) |
| ES (1) | ES2751920T3 (el) |
| GT (1) | GT201300178A (el) |
| HR (1) | HRP20191842T1 (el) |
| HU (1) | HUE045612T2 (el) |
| IL (1) | IL227094B (el) |
| JO (1) | JO3619B1 (el) |
| LT (1) | LT2661261T (el) |
| MA (1) | MA34897B1 (el) |
| MX (2) | MX357304B (el) |
| MY (1) | MY161162A (el) |
| PE (1) | PE20140216A1 (el) |
| PH (1) | PH12013501442B1 (el) |
| PL (1) | PL2661261T3 (el) |
| PT (1) | PT2661261T (el) |
| SG (1) | SG191286A1 (el) |
| SI (1) | SI2661261T1 (el) |
| TN (1) | TN2013000257A1 (el) |
| TW (2) | TWI583380B (el) |
| UA (1) | UA114283C2 (el) |
| WO (1) | WO2012093161A1 (el) |
| ZA (1) | ZA201304465B (el) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2661261T (pt) | 2011-01-07 | 2019-10-25 | Novartis Ag | Formulações imunossupressoras. |
| HUE054245T2 (hu) * | 2014-04-10 | 2021-08-30 | Novartis Ag | Immunszupresszáns formuláció |
| KR20160141841A (ko) * | 2014-04-10 | 2016-12-09 | 노파르티스 아게 | Ｓ１ｐ 조절제 즉시 방출 투여 요법 |
| WO2016135644A1 (en) | 2015-02-26 | 2016-09-01 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
| CA2989534C (en) | 2015-07-03 | 2023-08-01 | Astellas Pharma Inc. | Stable pharmaceutical composition for oral administration |
| US11629124B2 (en) | 2017-03-09 | 2023-04-18 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
| US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
| EP3687498B1 (en) | 2017-09-27 | 2025-01-22 | Novartis AG | Parenteral formulation comprising siponimod |
| WO2019064217A1 (en) | 2017-09-29 | 2019-04-04 | Novartis Ag | DOSAGE DIAGRAM OF SIPONIMOD |
| RU2020114750A (ru) | 2017-09-29 | 2021-10-29 | Новартис Аг | Схема введения доз сипонимода |
| CN109908095A (zh) * | 2019-04-08 | 2019-06-21 | 肇庆学院 | 一种西尼莫德片剂及制备方法 |
| WO2021214717A1 (en) | 2020-04-23 | 2021-10-28 | Novartis Ag | Dosing regimen for the use of siponimod for the treatment of acute respiratory distress syndrome |
| IL315531A (en) * | 2022-03-09 | 2024-11-01 | Isp Investments Llc | The composition of an inactive substance for drugs, produced by joint processing of its components |
| WO2024126409A1 (en) | 2022-12-12 | 2024-06-20 | Synthon B.V. | Pharmaceutical composition of siponimod |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3872113A (en) | 1972-05-30 | 1975-03-18 | Endo Lab | Hydroxy- and acetoxy-phthalaldehydric acid, O-(substituted) oximes |
| ES2126658T3 (es) | 1992-10-21 | 1999-04-01 | Yoshitomi Pharmaceutical | Compuesto de 2-amino-1,3-propanodiol e inmunosupresor. |
| AU703933B2 (en) | 1994-07-12 | 1999-04-01 | Berwind Pharmaceutical Services, Inc. | Moisture barrier film coating composition, method, and coated form |
| CA2213989C (en) | 1995-12-28 | 2007-05-29 | Yoshitomi Pharmaceutical Industries Ltd. | External preparation for topical administration |
| MY121470A (en) | 1999-05-03 | 2006-01-28 | Ranbaxy Lab Ltd | Stable solid pharmaceutical compositions containing enalapril maleate |
| AU2001285331B2 (en) | 2000-08-31 | 2006-04-06 | Merck & Co., Inc. | Phosphate derivatives as immunoregulatory agents |
| TW200305395A (en) | 2002-03-15 | 2003-11-01 | Novartis Ag | Organic compounds |
| EP1955696B1 (en) | 2002-05-16 | 2014-05-28 | Novartis AG | Use of the EDG receptor binding agent FTY720 in cancer |
| KR101030586B1 (ko) * | 2002-11-07 | 2011-04-21 | 다이쇼 세이야꾸 가부시끼가이샤 | 구강용 조성물 기제 및 구강용 조성물 |
| WO2004089341A1 (en) | 2003-04-08 | 2004-10-21 | Novartis Ag | Organic compounds |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| AU2004249664A1 (en) | 2003-05-19 | 2004-12-29 | Irm Llc | Immunosuppressant compounds and compositions |
| EP1628967B1 (en) | 2003-05-19 | 2014-04-09 | Irm Llc | Immunosuppressant compounds and compositions |
| EP1663188B1 (en) | 2003-09-12 | 2016-08-10 | Newron Sweden AB | Treatment of disorders of the nervous system |
| PE20050484A1 (es) | 2003-10-29 | 2005-10-13 | Wyeth Corp | Composicion farmaceutica de liberacion sostenida |
| US20090163523A1 (en) | 2004-05-03 | 2009-06-25 | Philip Lake | Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor |
| US20060002999A1 (en) | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
| EP2384749A1 (en) | 2004-11-29 | 2011-11-09 | Novartis AG | Dosage regimen of an S1P receptor agonist |
| EP1688141A1 (en) | 2005-01-31 | 2006-08-09 | elbion AG | The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome |
| GB0504544D0 (en) | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
| RU2296999C2 (ru) | 2005-03-09 | 2007-04-10 | Алексей Арнольдович Корженевский | Способ выявления критериев для проведения адекватной иммунотерапии гнойно-септических заболеваний |
| GT200600350A (es) | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
| RU2008113439A (ru) | 2005-09-09 | 2009-10-20 | Лабофарм Инк. (CA) | Композиции с замедленным высвобождением лекарственного средства |
| GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| WO2008072056A1 (en) | 2006-12-14 | 2008-06-19 | Pfizer Limited | Use of mtp inhibitors for the treatment of obesity using low doses and dose-escalation |
| DE102007019417A1 (de) | 2007-04-23 | 2008-11-13 | Grünenthal GmbH | Tapentadol zur Schmerzbehandlung bei Arthrose |
| US20100093672A1 (en) | 2007-05-04 | 2010-04-15 | Yves-Alain Barde | Use of s1p receptor modulator |
| SI2952177T1 (sl) * | 2007-10-12 | 2021-07-30 | Novartis Ag | Sestavki, ki vsebujejo modulatorje receptorja sfingozin 1 fosfata (s1p) |
| BRPI0909625B1 (pt) | 2008-03-17 | 2021-09-08 | Actelion Pharmaceuticals Ltd | Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1 |
| EP3545953A1 (en) | 2008-06-20 | 2019-10-02 | Novartis AG | Paediatric compositions for treating1 multiple sclerosis |
| BRPI0916232A2 (pt) | 2008-07-23 | 2017-08-29 | Novartis Ag | Moduladores do receptor de esfingosina-1-fosfato e seu uso para tratar inflamação muscular |
| JP5624037B2 (ja) * | 2008-08-18 | 2014-11-12 | ノバルティスアーゲー | 末梢神経障害の治療のための化合物 |
| KR20110112352A (ko) * | 2008-12-18 | 2011-10-12 | 노파르티스 아게 | 1-（4-｛ｌ-［（ｅ）-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노］-에틸｝-2-에틸-벤질）-아제티딘-3-카르복실산의 신규한 다형체 형태 |
| PL2676953T3 (pl) * | 2008-12-18 | 2017-09-29 | Novartis Ag | Sól hemifumaranowa kwasu 1-[4-[1-(4-cykloheksylo-3-trifluorometylobenzyloksyimino)-etylo]-2-etylobenzylo]-azetydyno-3-karboksylowego |
| CN102256941A (zh) * | 2008-12-18 | 2011-11-23 | 诺瓦提斯公司 | 新的盐 |
| EP2379141A1 (en) | 2008-12-19 | 2011-10-26 | Novartis AG | Mouthpiece for an inhaler |
| CN102264363A (zh) | 2008-12-22 | 2011-11-30 | 诺瓦提斯公司 | S1p受体激动剂的给药方案 |
| EP3409274B1 (en) | 2008-12-22 | 2019-11-20 | Novartis AG | Dosage regimen for a s1p receptor agonist |
| BR112012006957A2 (pt) | 2009-09-29 | 2016-06-14 | Novartis Ag | regime de dosagem de um modulador de receptor de s1p |
| PT2661261T (pt) | 2011-01-07 | 2019-10-25 | Novartis Ag | Formulações imunossupressoras. |
| WO2012095853A1 (en) | 2011-01-10 | 2012-07-19 | Novartis Pharma Ag | Modified release formulations comprising sip receptor modulators |
| TW201320994A (zh) | 2011-10-11 | 2013-06-01 | Novartis Ag | 投藥療程 |
| KR102166228B1 (ko) | 2013-04-04 | 2020-10-16 | 노파르티스 아게 | S1p 수용체 조절제 투여에 대한 환자 반응의 식별 |
| HUE054245T2 (hu) | 2014-04-10 | 2021-08-30 | Novartis Ag | Immunszupresszáns formuláció |
-
2012
- 2012-01-05 PT PT127002624T patent/PT2661261T/pt unknown
- 2012-01-05 MX MX2013007909A patent/MX357304B/es active IP Right Grant
- 2012-01-05 EP EP19188018.6A patent/EP3590507A1/en active Pending
- 2012-01-05 JO JOP/2012/0005A patent/JO3619B1/ar active
- 2012-01-05 PE PE2013001522A patent/PE20140216A1/es active IP Right Grant
- 2012-01-05 DK DK12700262.4T patent/DK2661261T3/da active
- 2012-01-05 AU AU2012204835A patent/AU2012204835B2/en active Active
- 2012-01-05 PH PH1/2013/501442A patent/PH12013501442B1/en unknown
- 2012-01-05 MA MA36170A patent/MA34897B1/fr unknown
- 2012-01-05 UA UAA201307576A patent/UA114283C2/uk unknown
- 2012-01-05 JP JP2013547861A patent/JP6111202B2/ja active Active
- 2012-01-05 WO PCT/EP2012/050151 patent/WO2012093161A1/en active Application Filing
- 2012-01-05 EA EA201391018A patent/EA026144B9/ru active Protection Beyond IP Right Term
- 2012-01-05 HU HUE12700262A patent/HUE045612T2/hu unknown
- 2012-01-05 EP EP12700262.4A patent/EP2661261B1/en active Active
- 2012-01-05 KR KR1020137020755A patent/KR101951966B1/ko active IP Right Grant
- 2012-01-05 KR KR1020197004860A patent/KR102166885B1/ko active IP Right Grant
- 2012-01-05 SI SI201231683T patent/SI2661261T1/sl unknown
- 2012-01-05 BR BR112013017302-5A patent/BR112013017302B1/pt active IP Right Grant
- 2012-01-05 PL PL12700262T patent/PL2661261T3/pl unknown
- 2012-01-05 CA CA2823616A patent/CA2823616C/en active Active
- 2012-01-05 ES ES12700262T patent/ES2751920T3/es active Active
- 2012-01-05 SG SG2013047923A patent/SG191286A1/en unknown
- 2012-01-05 MX MX2017007300A patent/MX371290B/es unknown
- 2012-01-05 LT LT12700262T patent/LT2661261T/lt unknown
- 2012-01-05 CN CN201280004869.2A patent/CN103458877B/zh active Active
- 2012-01-06 TW TW104142389A patent/TWI583380B/zh active
- 2012-01-06 MY MYPI2013002251A patent/MY161162A/en unknown
- 2012-01-06 AR ARP120100047A patent/AR084801A1/es not_active Application Discontinuation
- 2012-01-06 TW TW101100702A patent/TWI610672B/zh active
-
2013
- 2013-06-14 US US13/917,730 patent/US20130273161A1/en not_active Abandoned
- 2013-06-14 TN TNP2013000257A patent/TN2013000257A1/fr unknown
- 2013-06-18 ZA ZA2013/04465A patent/ZA201304465B/en unknown
- 2013-06-20 IL IL227094A patent/IL227094B/en active IP Right Grant
- 2013-07-05 GT GT201300178A patent/GT201300178A/es unknown
- 2013-07-05 CL CL2013001979A patent/CL2013001979A1/es unknown
- 2013-07-16 CO CO13168667A patent/CO6761402A2/es unknown
- 2013-08-07 EC ECSP13012812 patent/ECSP13012812A/es unknown
-
2017
- 2017-03-13 JP JP2017047220A patent/JP6324569B2/ja active Active
-
2019
- 2019-10-11 HR HRP20191842TT patent/HRP20191842T1/hr unknown
- 2019-10-22 CY CY20191101097T patent/CY1122182T1/el unknown
-
2020
- 2020-02-28 US US16/804,926 patent/US20200199069A1/en not_active Abandoned
-
2021
- 2021-04-14 US US17/230,175 patent/US12071402B2/en active Active
-
2022
- 2022-01-17 AR ARP220100086A patent/AR124662A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122182T1 (el) | Ανοσοκατασταλτικες φαρμακοτεχνικες μορφες | |
| CY1124882T1 (el) | Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn | |
| EA201690848A1 (ru) | Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4 | |
| EA202090530A1 (ru) | Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич | |
| CY1121625T1 (el) | Αναστολεις prmt5 και χρησεις αυτων | |
| CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| CY1120480T1 (el) | Ενωσεις πυραζολοπυριμιδινης | |
| EA201390908A1 (ru) | Производные бицикло[3.2.1]октиламида и их применение | |
| CY1123059T1 (el) | Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1 | |
| CY1118478T1 (el) | Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου για τη θεραπεια του πονου | |
| CY1123479T1 (el) | Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1 | |
| CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| CY1116645T1 (el) | Ενωση-αναστολεας σηματοδοτικου μονοπατιου notch | |
| CY1124243T1 (el) | Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1 | |
| EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
| EA201592199A1 (ru) | Производные бипиразола в качестве ингибиторов jak | |
| CY1118093T1 (el) | Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt | |
| EA202090688A1 (ru) | Бис-амидные соединения, активирующие саркомер, и варианты их применения | |
| CY1117122T1 (el) | Παραγωγα πυραζολοσπειροκετονης για χρηση ως αναστολεις ακετyλ-coa καρβοξυλασης | |
| EA201290632A1 (ru) | Производные бетулина | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| EA201691119A1 (ru) | Производные мочевины или их фармакологически приемлемые соли | |
| CY1122313T1 (el) | Ορβεπιταντη για την αγωγη του χρονιου κνησμου | |
| CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια |